OncoSec to Host Third Quarter Financial Conference Call on June 1, 2017

SAN DIEGO, May 11, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company will host its fiscal third quarter 2017 financial results conference call on Thursday, June 1 at 1:15 PM PT/4:15 PM ET.

To access the audio broadcast, please dial (877) 731- 1960 and enter the conference ID number: 20167930. An archived version of the presentation will be available for 90 days on the "Investors" section of OncoSec's website: http://ir.oncosec.com/events-presentations.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer.  ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several indications, including metastatic melanoma, and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT:
Investor Relations 
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com

Media Relations 
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-host-third-quarter-financial-conference-call-on-june-1-2017-300455972.html

SOURCE OncoSec Medical Incorporated